Early activated hepatic stellate cell-derived molecules reverse acute hepatic injury

Figure 4 Hepatic stellate cell-CM (5d) provides a survival benefit in acute liver injury mice and reverses acute liver injury in a cell mass-dependent manner. A: Kaplan-Meier survival analysis of acetaminophen (APAP)-administered mice treated with concentrated hepatic stellate cell (HSC)-CM (0.2 mL, conditioned medium of 2 × 10⁶ cells HSCs). Control mice received vehicle (0.2 mL, high-glucose DMEM). The results for both panels are cumulative data of two independent experiments (n = 13 per group). The number of death mice during survival analysis in each group: 9 in vehicle, 3 in HSC (5d), and 7 in HSC (P3). P-values were determined by the Kaplan-Meier analysis, ^aP < 0.05 vs control; B: Dose-response graph of animal survival 72 h after acute liver injury (ALI) induction as a function of the mass of HSCs (5d) from which HSC-CM was derived; alanine aminotransferase (C), aspartate aminotransferase levels (D) in peripheral blood samples collected at 12, 24, 36, and 48 h after the systemic treatment. ^bP < 0.01 vs control. NS: No significant.